Philogen announces publication of malignant brain tumor study results in Science Translational Medicine.

  Press Release


Philogen will be attending the World ADC Digital Conference from September 15 to 18, 2020.
Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Plenary Lecture on: “Small Molecule-drug Conjugates (SMDCs) & ADCs: A Comparative Evaluation”.


Our co-founder and Chief Scientific Officer, Prof. Dario Neri will join Philogen in a full time capacity. His professional path is featured on the ETH Zurich web site. Read the full story here.

  Always ask the important questions


Philogen announces a publication entitled: “A microdosing study with 99mTc-PHC-102 for the SPECT/CT imaging of primary and metastatic lesions in renal cell carcinoma patients”
Link to Paper


Philogen received clinical trial authorisation with NIDLEGYTM in nonmelanoma skin cancer

  NIDLEGY authorisation in nonmelanoma skin cancer

Philogen received combination pack approval for NidlegyTM

  PR Nidlegy Combination Pack Approval


Philogen announces Option Exercise by Janssen


  PR Option Exercise by JANSSEN

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy